Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two ...

The patients had no weight loss plateau and up to 99 per cent of them lost more than 5 per cent of their body weight. More recently, Metsera announced the Phase IIa results for its MET-097i candidate.

The solution?: Lose weight. But the report, published in the journal The Lancet Diabetes & Endocrinology on Tuesday, suggested that having obesity according to the BMI scale doesn't mean a person ...

减肥药研发公司Metsera在上周五向美国证券交易委员会(SEC)提交了首次公开募股(IPO)申请，旨在筹集1亿美元资金。该公司计划在纳斯达克上市，股票代码定为“MTSR”。Metsera专注于治疗肥胖及代谢疾病，致力于开发下一代可注射和口服营养刺激激素(NuSH)类似肽 ...

Other newcomers to the weight-loss drug field include Kailera Therapeutics, which launched in October with $400 million in funding, and Metsera, which debuted in April with $290 million and has ...